Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial

YouTube (Lucid Quest) USA

Overview

A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO’s RGX-202, a gene therapy for Duchenne muscular dystrophy, achieved its primary endpoint in an ongoing Phase 3 clinical trial. Other notable mentions include Beam Therapeutics’ BEAM-302 data for AATD presented at ATS 2026, a new collaboration between Regeneron and Parabilis, EMA acceptance for Otarmeni’s hereditary hearing loss therapy, and preclinical data for TreeFrog’s TFG-001 in Parkinson’s disease models.

In Depth

Key Findings

According to the Gene and Cell Therapy Update released on May 28, 2026, Vyjuvek, a treatment for dystrophic epidermolysis bullosa (DEB), has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This marks a significant milestone, representing the first gene therapy for this debilitating skin condition to become available in the UK, offering substantial hope to patients. Simultaneously, REGENXBIO announced that its gene therapy, RGX-202, for Duchenne muscular dystrophy (DMD), achieved its primary endpoint in an ongoing Phase 3 clinical trial, opening new avenues for DMD treatment.

Technical and Clinical Details

Vyjuvek is a topically applied gene therapy designed to promote skin healing in DEB patients by introducing the deficient type VII collagen gene into skin cells. The UK MHRA approval confirms its safety and efficacy after rigorous evaluation. RGX-202, on the other hand, is an adeno-associated virus (AAV)-based gene therapy that delivers a microdystrophin gene to muscle cells, aiming to address the underlying cause of DMD. Achieving the primary endpoint in the Phase 3 trial underscores its clinical significance and potential to improve patient outcomes. Furthermore, Beam Therapeutics presented promising data for BEAM-302 in AATD at ATS 2026, and TreeFrog shared preclinical data for TFG-001 in Parkinson’s disease models.

Background and Industry Context

The field of gene therapy has experienced revolutionary progress in recent years, particularly in its potential to offer curative approaches for rare and genetic diseases that were previously untreatable. Vyjuvek’s approval in a major market like the UK, following its FDA approval, is a critical step towards global availability. The advancement of RGX-202 offers a new therapeutic option for DMD, a progressive and debilitating disease, bringing hope to patients and their families. These developments indicate growing regulatory understanding and support, paving the way for more innovative gene therapies to reach clinical practice.

Future Outlook

The market entry of Vyjuvek in the UK has the potential to significantly enhance the quality of life for DEB patients, with further approvals anticipated in other regions. The success of RGX-202 further solidifies the role of gene therapy in DMD treatment and heightens expectations for its future market launch. While challenges such as expanding manufacturing capacity, improving accessibility, and establishing health economics remain for widespread adoption, these advancements unequivocally demonstrate cell and gene therapy’s central role as a pillar of next-generation medicine.